TY - JOUR
T1 - Effect of aerobic exercise training dose on liver fat and visceral adiposity
AU - Keating, Shelley E.
AU - Hackett, Daniel A.
AU - Parker, Helen M.
AU - O'Connor, Helen T.
AU - Gerofi, James A.
AU - Sainsbury, Amanda
AU - Baker, Michael K.
AU - Chuter, Vivienne H.
AU - Caterson, Ian D.
AU - George, Jacob
AU - Johnson, Nathan A.
N1 - Funding Information:
This research was supported by funding from the Diabetes Australia Research Trust . (Establishment Grant: N.A. Johnson). JG is supported by the Robert W. Storr Bequest to the Sydney Medical Foundation , University of Sydney ; a National Health and Medical Research Council of Australia ( NHMRC ) Program Grant ( 1053206 ) and a Project grant ( 1049857 ). AS is supported by fellowships from the University of Sydney/Sydney Medical School and the National Health and Medical Research Council. The funding bodies had no role in the design of the study, collection and analysis of data or decision to publish. The authors declare that there are no competing financial interests in relation to the work described. Australian New Zealand Clinical Trial Registry Number: ACTRN12614000723684.
Funding Information:
S.E. Keating, D.A. Hackett, H.M. Parker, M.K Baker, V.H. Chuter, H.T. O’Connor, J.A. Gerofi, and A. Sainsbury declare no conflict of interest. N.A. Johnson: has received honoraria for speaking engagements for Merck Sharp & Dohme. I.D. Caterson: has performed and still performs clinical trials of obesity treatment and prevention some of which have been funded by government, but others by the pharmaceutical industry. Current trials are funded by the NHMRC [3] , NovoNordisk, Amylin Corporation, the Egg Board. He serves on the steering committees of international trials (SCOUT and EXSCEL) and has received honoraria for this. He has given talks for NovoNordisk, Servier Laboratories, Pfizer and iNova pharmaceuticals in the last 3 years. He serves on the scientific advisory board of the Sansom Institute for Health Research, University of SA, the board of the Children’s Medical Research Institute, and chairs the Executive Management Committee of the bariatric surgical register for the Obesity Surgery Society of Australia and New Zealand. JG has no conflicts to declare in relation to this submission.
Publisher Copyright:
© 2015 European Association for the Study of the Liver.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Background & Aims Aerobic exercise reduces liver fat and visceral adipose tissue (VAT). However, there is limited data from randomized trials to inform exercise programming recommendations. This study examined the efficacy of commonly prescribed exercise doses for reducing liver fat and VAT using a randomized placebo-controlled design. Methods Inactive and overweight/obese adults received 8 weeks of either; i) low to moderate intensity, high volume aerobic exercise (LO:HI, 50% VO2peak, 60 min, 4 d/week); ii) high intensity, low volume aerobic exercise (HI:LO, 70% VO2peak, 45 min, 3 d/week); iii) low to moderate intensity, low volume aerobic exercise (LO:LO, 50% VO2peak, 45 min, 3 d/week); or iv) placebo (PLA). Liver fat (spectroscopy) and VAT (magnetic resonance imaging) were measured before and after intervention. Results Forty-seven of the 48 (n = 12 in each group) participants completed the trial. There were no serious adverse events. There was a significant change in group × time interaction in liver fat, which reduced in HI:LO by 2.38 ± 0.73%, in LO:HI by 2.62 ± 1.00%, and in LO:LO by 0.84 ± 0.47% but not in PLA (increase of 1.10 ± 0.62%) (p = 0.04). There was a significant reduction in VAT in HI:LO (-258.38 ± 87.78 cm3), in LO:HI (-386.80 ± 119.5 cm3), and in LO:LO (-212.96 ± 105.54 cm3), but not in PLA (92.64 ± 83.46 cm3) (p = 0.03). There were no significant differences between the dose or intensity of the exercise regimen and reductions in liver fat or VAT (p >0.05). Conclusion The study found no difference in efficacy of liver fat reduction by either aerobic exercise dose or intensity. All of the aerobic exercise regimens employed reduced liver fat and VAT by a small amount without clinically significant weight loss.
AB - Background & Aims Aerobic exercise reduces liver fat and visceral adipose tissue (VAT). However, there is limited data from randomized trials to inform exercise programming recommendations. This study examined the efficacy of commonly prescribed exercise doses for reducing liver fat and VAT using a randomized placebo-controlled design. Methods Inactive and overweight/obese adults received 8 weeks of either; i) low to moderate intensity, high volume aerobic exercise (LO:HI, 50% VO2peak, 60 min, 4 d/week); ii) high intensity, low volume aerobic exercise (HI:LO, 70% VO2peak, 45 min, 3 d/week); iii) low to moderate intensity, low volume aerobic exercise (LO:LO, 50% VO2peak, 45 min, 3 d/week); or iv) placebo (PLA). Liver fat (spectroscopy) and VAT (magnetic resonance imaging) were measured before and after intervention. Results Forty-seven of the 48 (n = 12 in each group) participants completed the trial. There were no serious adverse events. There was a significant change in group × time interaction in liver fat, which reduced in HI:LO by 2.38 ± 0.73%, in LO:HI by 2.62 ± 1.00%, and in LO:LO by 0.84 ± 0.47% but not in PLA (increase of 1.10 ± 0.62%) (p = 0.04). There was a significant reduction in VAT in HI:LO (-258.38 ± 87.78 cm3), in LO:HI (-386.80 ± 119.5 cm3), and in LO:LO (-212.96 ± 105.54 cm3), but not in PLA (92.64 ± 83.46 cm3) (p = 0.03). There were no significant differences between the dose or intensity of the exercise regimen and reductions in liver fat or VAT (p >0.05). Conclusion The study found no difference in efficacy of liver fat reduction by either aerobic exercise dose or intensity. All of the aerobic exercise regimens employed reduced liver fat and VAT by a small amount without clinically significant weight loss.
KW - Abdominal fat
KW - NAFLD
KW - Obesity
KW - Physical activity
KW - Weight loss
UR - http://www.scopus.com/inward/record.url?scp=84931577976&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2015.02.022
DO - 10.1016/j.jhep.2015.02.022
M3 - Article
C2 - 25863524
AN - SCOPUS:84931577976
SN - 0168-8278
VL - 63
SP - 174
EP - 182
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 1
M1 - 5568
ER -
